What АСК-кардио Treats: Main Uses and Benefits

The primary therapeutic domain of АСК-кардио is the continuous, long-term antiplatelet management of conditions marked by increased physiological stress, focusing on vascular health. This medication is commonly used to help manage the risk associated with established heart and vascular disease, including stable or unstable angina, peripheral arterial disease (PAD), and atherosclerotic cerebrovascular disease. The therapy is commonly used as a component of secondary prevention for patients who have previously suffered a myocardial infarction (heart attack), ischemic stroke, or transient ischemic attack (TIA).

The use of this therapy assists in easing the overall symptom load by playing a role in managing the reduction of subsequent serious vascular events. Furthermore, it supports the patient during difficult episodes of circulatory strain and is used for post-procedural support following coronary stenting or bypass surgery.

“This sustained antiplatelet support is relevant for managing symptoms that interfere with daily comfort and supports patients during episodes of heightened discomfort.”

---

Quick Fact: Focus on Thrombotic Risk Management

Property	Description
Primary Use	Focus on Reducing Event Recurrence
Symptom Axis	Symptoms linked to organ-specific functional stress
Benefit Focus	Supports the reduction of recurrence risk
Context	Long-term chronic disease management

---

This selective intervention is also considered relevant for primary prevention in high-risk adults (typically aged 40 to 59) whose risk profile is considered relevant for preventative intervention, contributing to easing the overall symptom burden by playing a role in reducing the potential for a first major cardiovascular event.

Regulatory References

1. NHS Antiplatelet Guideline

Eligibility Map: Who can and cannot use АСК-кардио — Official Regulatory Information

The eligibility profile for АСК-кардио (Acetylsalicylic Acid, antiplatelet) is defined by official regulatory bodies, focusing on patient safety and exclusion criteria.

Contraindicated Populations and Conditions

Use is strictly prohibited in patients with known hypersensitivity to ASA, salicylates, or NSAIDs. It is contraindicated for individuals with active pathological bleeding conditions, including active peptic ulcer disease or severe hemorrhagic diathesis. Individuals with severe hepatic impairment, severe renal impairment, or severe uncontrolled cardiac insufficiency must not use this medicine.

Age and Pregnancy Restrictions

АСК-кардио is contraindicated in children and adolescents under 16 years due to the documented risk of Reye's syndrome. Use is also contraindicated during the third trimester of pregnancy (after 20 weeks). For primary prevention of cardiovascular events, initiating therapy is not recommended for adults 60 years or older.

Eligibility-Related Restrictions

Conditional use is required in patients with mild to moderate hepatic or renal impairment, where therapeutic experience is limited. Use with caution is advised for patients with a history of gastrointestinal ulcers, asthma, or those who consume heavy amounts of alcohol.

Interactions with other medicines and products

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Oral Anticoagulants, Other Antiplatelet Agents, Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Uricosurics, Selective Serotonin Re-uptake Inhibitors (SSRIs), ACE Inhibitors, Diuretics.
Specific interacting medicines (if explicitly listed)	Methotrexate, Digoxin, Pemetrexed, Probenecid, Ibuprofen, Naproxen.
Mechanistic basis of interactions (only if stated in label)	Reduced renal clearance (affects Methotrexate, Digoxin, Pemetrexed); Inhibition of tubular resorption of uric acid (affects Uricosurics); Additive antiplatelet effect (affects Anticoagulants/Antiplatelets).
Timing-based interaction rules (if applicable)	Co-administration with Ibuprofen may require timing separation to prevent attenuation of the antiplatelet effect.
Population-specific interaction notes (if applicable)	Interaction resulting in renal function deterioration with ACE Inhibitors/Diuretics is heightened in elderly or volume-depleted patients.
Interaction-related restrictions	Contraindicated with Methotrexate doses ge 15 mg/week. Contraindicated with Oral Anticoagulants in patients with a history of GI ulcers.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Statement
Interaction severity classification (as defined in official documents)	Contraindicated (e.g., high-dose Methotrexate); Not Recommended (e.g., other NSAIDs); Use with Caution (e.g., SSRIs, Antihypertensives).
Regulatory basis (EMA / FDA / etc.)	Information derived from FDA Prescribing Information, EMA Summary of Product Characteristics (SmPC), and national regulatory authority guidelines.
Interaction-context constraints (as defined in official documents)	Interactions are conditional on factors like the dosage of the co-administered drug, the patient’s existing co-morbidities, or physiological state.

---

Official Interaction Statements:

• Co-administration with Methotrexate (doses ge 15 mg/week) is contraindicated due to increased haematological toxicity.
• Concomitant use with Oral Anticoagulants and other Antiplatelet Agents increases the risk of haemorrhage due to additive pharmacodynamic effects.
• ASA reduces the efficacy of Uricosuric agents by inhibiting the renal tubular elimination of uric acid.
• Co-administration with Digoxin increases Digoxin plasma concentrations due to a decrease in its renal excretion.
• Chronic heavy alcohol consumption increases the risk of gastrointestinal bleeding.
• ASA diminishes the antihypertensive effect of agents such as ACE Inhibitors and Diuretics.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define the product’s interaction structure primarily through two domains: Additive Haemostatic Risk and Altered Systemic Exposure of co-administered drugs. The profile establishes several formal restrictions, including contraindications based on dosage or patient history, and flags pharmacodynamic effects, such as increased bleeding potential. This structure consistently mandates evaluation of specific co-administered drug classes to manage the resulting toxicity or reduced efficacy as described in the official label.

Irreversible Inactivation of the Platelet Enzyme COX-1

The core action of the drug involves the permanent deactivation of the Cyclooxygenase-1 (COX-1) enzyme found within blood platelets by chemically altering its structure. This irreversible modification functionally silences the enzyme, preventing it from converting arachidonic acid into pro-aggregatory chemical messengers.

Sustained Suppression of Thromboxane A2 (TXA2) Signaling

Because blood platelets are anucleated (lacking a nucleus), they are unable to synthesize new COX-1 enzyme to replace the inactivated molecules. This leads to a profound suppression of TXA2 synthesis for the entire lifespan of the platelet (approximately 7–10 days). This sustained suppression of the TXA2-dependent pathway results in a continuous anti-aggregatory state that persists for the lifespan of the platelet.

Formulation Constraints on Mechanistic Onset

The drug’s mechanism is functionally constrained by its delivery system: the gastroresistant tablet delays the release and absorption of the active ingredient until it leaves the stomach. This mechanical delay directly influences the rate at which the enzyme target is acetylated, resulting in a slower kinetic profile for the onset of the antiplatelet effect.

How to Use АСК-кардио: Administration Guidelines

---

АСК-кардио is a specialized formulation of Acetylsalicylic Acid intended for continuous, long-term antiplatelet therapy. Standard protocols exist to ensure proper administration of the gastro-resistant tablet form.

Administration Scope

Feature	Detail from Official Guidelines
Route of administration	Oral administration only.
Dosing schedule (maintenance)	Maintenance dose is typically 75 mg to 150 mg daily. A short-term initial dose of up to 300 mg may be used in certain acute circumstances before transitioning to the maintenance regimen.
Timing in relation to meals	Best taken with or just after food to help mitigate potential gastric irritation.
Age-group administration rules	The product is generally not indicated for routine use in children and adolescents under 16 years, unless specifically advised by a physician.
Missed-dose rules	If a dose is missed, skip the missed dose and take the next dose at the regular time. Do not take a double dose to compensate.

---

Resulting Procedural Structure

The procedural structure for administration is designed to maintain the integrity of the gastro-resistant tablet. The tablet must be swallowed whole with sufficient fluid, typically water, and must not be crushed, chewed, or broken before swallowing. This instruction is essential for ensuring the drug's intended release profile. This treatment establishes a fixed, once-daily, low-dose regimen intended for continuous use over an indefinite duration.

Evidence for Use in Secondary Prevention of Vascular Events

This research base details the use of the medicine for individuals who have already experienced a major vascular event (such as a heart attack or stroke) or who have established cardiovascular conditions. Large-scale Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses observed thousands of participants, primarily monitoring the recurrence of a major vascular event, outcomes related to survival, and patterns in populations following procedures like stenting. The data show patterns related to a lower observed occurrence of recurrent vascular events in the studied groups. However, a persistent finding reported across the research base is a simultaneous pattern of increased occurrence of major bleeding events. Comparative evidence is lacking against all of the newer, alternative antiplatelet agents used in contemporary practice.

Evidence for Use in Primary Prevention in High-Risk Adults

This section summarizes the dedicated clinical trials that were studied for individuals at high risk for a first-time vascular event but with no prior history. These trials tracked outcomes over intermediate to long-term periods, typically ranging from five to seven years. Studies primarily monitored the incidence of a first event and concurrently evaluated the risk of major bleeding. Findings were mixed across the large studies, with some reporting limited measured differences in event occurrence. This outcome is associated with the evidence level being considered moderate, where the potential event outcomes are weighed against the observed bleeding patterns.

Long-Term Research and Uncertainty

The research structures supporting secondary prevention explored outcomes over long-term observation periods relevant to continuous cardiovascular management. Data show patterns related to uncertainty for older adults (over 70), where the pattern of increased major bleeding events appears more pronounced, and the certainty regarding event outcomes remains low. The data available for the full long-term effects of the medicine after many decades of use are not fully established. A major research gap is how the concurrent use of other therapies influences the independent contribution of this medicine, which continues to be explored.

Key Studies & References

1. Aspirin Delayed-Release Tablet (Acetylsalicylic Acid) Label - DailyMed
2. Secondary prevention of coronary heart disease and stroke: antiplatelet guideline

Common questions about АСК-кардио (FAQ)

Q: What is the difference between АСК-кардио and regular aspirin?

A: Official product information describes АСК-кардио as a specialized, low-dose formulation of acetylsalicylic acid that includes a gastro-resistant or enteric coating. This coating is designed to prevent the tablet from dissolving in the stomach, thereby minimizing direct contact with the gastric lining. This feature is the key difference from immediate-release aspirin preparations.

Q: Can I take АСК-кардио if I am pregnant or breastfeeding?

A: Regulatory information indicates that use during the third trimester of pregnancy is contraindicated due to the potential for fetal harm. For the first two trimesters and during the period of breastfeeding, the medicine is generally recommended only if clearly advised and closely supervised by a healthcare professional.

Q: Is it true that АСК-кардио prevents heart attacks?

A: Official documents describe the medicine’s primary role in the secondary prevention of serious vascular events, such as recurrent heart attacks or ischemic strokes, in individuals who already have established cardiovascular conditions. The regulatory language focuses on reducing the observed occurrence of these events, rather than claiming a guarantee of prevention.

Q: Can older people use АСК-кардио safely?

A: For the purpose of primary prevention (in those who have not had a previous event), official guidelines advise against initiating therapy for adults aged 60 years or older. For secondary prevention, the risk of major bleeding is documented as being more pronounced in older adults, specifically those over 70.

Q: Why do doctors prescribe АСК-кардио instead of regular aspirin for heart issues?

A: The gastro-resistant tablet form of АСК-кардио is specifically designed to bypass the stomach and dissolve in the intestine. This specialized coating supports long-term, continuous daily therapy by minimizing direct contact with the gastric lining, which is an important consideration for patient adherence in chronic cardiovascular risk management.

Q: What does the term 'cardioprotective dose' mean for АСК-кардио?

A: The term generally refers to the low daily dose of acetylsalicylic acid that is sufficient to achieve the desired antiplatelet effect. Official guidelines typically define this as the range needed for continuous, long-term prevention of blood clots in the circulatory system.

Q: Is there evidence that АСК-кардио helps prevent strokes?

A: Regulatory evidence supports the use of this medicine for the secondary prevention of major vascular events. This indication includes reducing the recurrence of ischemic strokes in high-risk patients who have already experienced such an event.

Q: Can I stop taking АСК-кардио suddenly?

A: The medication is intended for continuous, long-term antiplatelet therapy. Official advice for this drug class often states that abrupt discontinuation should not occur without consulting a healthcare professional, as the antiplatelet effect persists for approximately 7 to 10 days, which is the lifespan of the platelet.

Q: What happens if I miss a dose of АСК-кардио?

A: Official administration guidelines strictly state that if a dose is missed, it should be skipped, and the patient should take the next dose at the regular time. Regulatory instructions advise against taking a double dose in order to compensate for a missed one.

Q: How long does it take for АСК-кардио to start working?

A: The specialized gastro-resistant coating causes the release and absorption of the active ingredient to be delayed until the tablet leaves the stomach. This mechanical constraint results in a slower kinetic profile for the onset of the medicine's antiplatelet effect compared to non-coated aspirin.

Q: Does АСК-кардио interact with herbal supplements?

A: Official regulatory documents on drug interactions primarily list other prescription and over-the-counter medicines. Patients using any herbal or nutritional supplements are informed by regulatory documents to discuss them with a healthcare provider, especially due to the potential for an additive bleeding risk with certain agents, such as Ginkgo.

Q: Why are there different strengths of АСК-кардио?

A: The availability of different strengths (e.g., 75 mg and 150 mg) aligns with the dose ranges defined in official administration guidelines. A lower daily dose is typical for a continuous maintenance regimen, while a higher dose may be used short-term in certain acute circumstances before transitioning to the long-term therapy.

Q: What should I do if I get a bruise easily while on АСК-кардио?

A: Increased bruising is listed in official documents as a common hemorrhagic side effect. Official safety information directs patients to monitor for signs of more serious, systemic bleeding, such as black or tarry stools or vomiting material that looks like coffee grounds, which require immediate medical attention.

Q: Is АСК-кардио suitable for people who have never had a heart problem?

A: The use of the medicine for individuals who have never experienced a major vascular event is referred to as primary prevention. Official guidelines state that the decision to initiate this therapy should be made on an individual basis, carefully considering a person’s absolute cardiovascular risk factors and their existing risk of bleeding.

Q: Does taking АСК-кардио affect blood donation?

A: Official information confirms that taking the medication affects the function of blood platelets. As a result, individuals taking АСК-кардио are generally prohibited from donating blood components that rely on normal platelet function, such as platelets. Individuals should check the specific eligibility rules of their blood donation center.

Q: Can АСК-кардио affect my liver function?

A: Official safety information lists signs of liver problems (such as yellowing of the skin or eyes) as a serious side effect requiring medical attention. Furthermore, severe hepatic impairment is also explicitly listed as a contraindication to using this medicine.

Q: How is the safety of АСК-кардио monitored after it is released?

A: Following regulatory approval, the safety of the medicine continues to be monitored through a formal post-marketing surveillance system. This involves the continuous collection and review of adverse drug experience reports submitted by patients and healthcare professionals to the responsible regulatory agency.

Q: Does АСК-кардио have a specific shelf life or storage requirement?

A: Like all approved medicines, АСК-кардио has an expiration date, which represents the officially determined shelf life for optimal potency and stability. The medicine must be kept in its original, closed container and stored at controlled room temperature, protected from both light and moisture.

Q: Are there research studies looking at new uses for АСК-кардио?

A: Regulatory bodies and research institutions like the NIH maintain records of ongoing clinical trials and studies examining acetylsalicylic acid. These research efforts may explore various medical areas and potential new uses outside of the currently approved cardiovascular indications.

Q: Does research support the use of АСК-кардио for primary prevention?

A: Official summaries of primary prevention trials indicate that the findings regarding event occurrence were mixed, which results in the evidence being considered moderate. This outcome is associated with the need to carefully weigh the potential benefits against the observed risk of major bleeding patterns.

Q: Are there specific groups of patients who benefit most from АСК-кардио?

A: Regulatory guidelines related to primary prevention indicate that the small potential benefit is considered most likely for selected individuals between the ages of 40 and 59 who have a cardiovascular disease risk greater than 10% over ten years and who are not at an increased risk for bleeding.

Q: How does АСК-кардио compare to other antiplatelet drugs?

A: Official research summaries note that comparative evidence against all of the newer, alternative antiplatelet agents used in contemporary practice is lacking. Regulatory documentation primarily focuses on the established efficacy and safety profile of acetylsalicylic acid itself.

Q: Can I take АСК-кардио with cholesterol-lowering drugs?

A: Official interaction tables generally list drug classes where caution is advised or co-administration is restricted. Specific interaction warnings related to common cholesterol-lowering medicines, such as statins, are typically not listed in the contraindication or major interaction sections of regulatory documents.

How to Store and Dispose of АСК-кардио

Official regulatory guidelines strictly define the storage and disposal of АСК-кардио to preserve the stability of the acetylsalicylic acid and the gastroresistant coating.

---

Storage Requirements

The medicine must be stored at Controlled Room Temperature, typically not exceeding 25 C or 30 C. The product must be kept in its original, tightly closed container and requires protection from both light and moisture. It is prohibited to freeze the medication.

---

Handling and Disposal

Storage must always be out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired tablets must be discarded according to local regulations for pharmaceutical waste. The product must not be flushed down a drain or toilet to avoid environmental contamination.